Medical Advisory Standards & 503A Intranasal Compounding Verification
Intranasal PT-141 & SubQ Clinical Protocol Directory was created as an independent informational guide to help men and women compare physician-supervised 503A compounded PT-141 nasal spray and subcutaneous injection options—and see how they outperform traditional oral ED pills—without acting as a doctor or selling medications directly.
1. Licensed 503A Mucosal & SubQ Pharmacies
Every telehealth platform and clinic we list dispenses exclusively through state-board-licensed 503A compounding pharmacies offering both metered nasal atomizers and subcutaneous vials.
2. Strict Contraindication Screening
Because Bremelanotide transiently elevates systolic blood pressure by 3 to 6 mmHg, our informational quiz automatically flags uncontrolled hypertension and active cardiovascular disease.
3. 72-Hour Receptor Hygiene
We highlight the FDA-validated ceiling of max 1 dose per 24 hours and max 8 doses per month (minimum 72 hours apart) to prevent MC4R receptor tolerance and MC1R hyperpigmentation.